Abstract
Panax ginseng, an ancient herb, belonging to Chinese traditional medicine, is an important herb that has a remarkable impact on various diseases. Ginsenoside Rg3, one of the most abundant ginsenosides, exerts significant functions in the prevention of various types of cancers with few side effects. In the present review, its functional molecular mechanisms are explored, including the improvement of antioxidant and anti-inflammation properties, immune regulation, induction of tumor apoptosis, prevention of tumor invasion and metastasis, tumor proliferation and angiogenesis, and reduction of chemoresistance and radioresistance. On the other hand, metabolism, pharmacokinetics and clinical indications of Rg3 are also discussed. The biological functional role of ginsenoside Rg3 may be associated with that it is a steroid glycoside with diverse biological activities and many signaling pathway can be regulated. Many clinical trials are highly needed to confirm the functions of ginsenoside Rg3.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Panax ginseng, an ancient herb, belonging to Chinese traditional medicine, is an important herb that has clear effects on the treatment of diverse diseases [1,2,3]. Ginsenoside, a class of steroid glycosides, is one of the dominant secondary metabolites in ginseng and armed with various pharmacological activities [4,5,6]. Ginsenoside Rg3, one of the most abundant ginsenosides, has been explored in the prevention of inflammation [7], diabetes [8, 9], and cardiovascular diseases [10]. Cancer is the first cause of death followed by ischemic heart disease and stroke in the world [11]. The antitumor activities of ginsenoside Rg3 have been explored in many types of cancers, including the induction of apoptosis, inhibition of tumor growth, proliferation, metastasis invasion and angiogenesis, and cell cycle arrest (Table 1). In order to better understand its function in various anti-tumor activities, the related molecular mechanisms of Ginsenoside Rg3 in the prevention of various cancer risks were reviewed in the present paper.
Ginsenoside Rg3 improves anti-inflammatory capacity
Chronic inflammation plays a critical role in the development of various types of cancers, from initiation, progression to metastasis [12, 13] and worsens the outcomes of cancer patients. T cell cytokines are related to various clinical aspects of hepatocellular carcinoma (HCC), and interleukin (IL)-6 is the most suggestive predictor of survival [14]. Inflammatory cytokines including interferon-(IFN)-α, -β, and -γ; interleukin-(IL) -2, -6, and -10, and tumor necrosis factor (TNF)-α are all associated with breast cancer development [15].
Ginsenoside Rg3 has been proposed to ameliorate various inflammatory diseases in animal models, including T-cell-mediated inflammation diseases [16]. Rg3 can attenuate inflammatory status in a rat model by decreasing serum TNF-α, IL-1β and IL-6 levels and increasing serum IL-10 levels [17]. Further work indicates that ginsenoside Rg3 can attenuate lipopolysaccharide (LPS)-induced acute lung injury (ALI) by decreasing the levels of pro-inflammatory mediators and increasing the production of anti-inflammatory cytokines via Mer tyrosine kinase (MerTK)-dependent activation of the via phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway [18]. Ginsenoside Rg3 may also improve anti-inflammatory capacity by affecting PI3K/AKT/mTOR signaling pathway through Toll-like receptor 4 (TLR4), which is a potential target of ginsenoside Rg3 (Fig. 1) [19]. The anti-inflammatory role of ginsenoside Rg3 may be associated with its structure, a steroid glycoside. Steroid-like anti-inflammatory activity has also been widely reported [20, 21]. Steroid drug has been widely used in cases of inflammatory disorders by suppressing proinflammatory cytokines IL-1, IL-2, IL-6, IL-8, IFN-γ and TNF-α [22]. These findings provide a new view of the specific anti-inflammatory mechanism of ginsenoside Rg3.
Ginsenoside Rg3 increases antioxidant properties
Contingent upon concentration, reactive oxygen species (ROS) influence cancer evolution and can initiate or stimulate tumorigenesis [23]. Antioxidants are regarded to play an important role to control ROS levels. Free radicals commonly cause oxidative damage which is a vital factor of formation, and development of cancers. Antioxidants belong to natural and synthetic origin have been tested in clinical trials against oxidative stress, and may be beneficial in cancer control [24]. Ginsenoside Rg3 having antioxidant potential is used in the treatment of cancers by regulating ROS levels [25], which include oxygen ions/O2., free radicals (superoxide/O2− and hydroxyl radicals/·OH) and peroxides (hydrogen peroxide/H2O2) in tumor cells [26, 27]. Ginsenoside Rg3 plays an important role in antioxidant activities, and is known to exert antioxidant effects by increasing the activity of antioxidant enzymes and related biomolecules, which can scavenge free radicals [28]. Ginsenoside Rg3 has been found to induce the activity of intracellular antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and glutathione reductase (GR) (Fig. 2a) [29], which is involved in scavenging free radicals (Fig. 2b). The antioxidant ability of ginsenoside Rg3 may be due to its steroid structure since steroid drugs have been widely reported to have antioxidant activities [30].
Ginsenoside Rg3 induces cancer cell apoptosis
Apoptosis induction is a potential approach and has been developed as the therapeutic methods for promoting the effective elimination of cancer cells [31]. The combination of ginsenoside Rg3 and 5-FU promotes the apoptosis of colon cancer cells in vitro by affecting PI3K/Akt signaling pathway [32]. Ginsenoside Rg3 stimulates cytotoxicity and apoptosis of Paclitaxel by preventing nuclear factor kappa B (NF-κB) signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer and should be regarded as a good chemosensitizing agent for cancer treatment [32].
Ginsenoside Rg3-based polypeptide nanoparticles is effective in the treatment of colon cancer by inducing cancer cell apoptosis [33]. The combination of oxaliplatin and ginsenoside Rg3 increased the anti-tumor effect and may inhibit the proliferation and promote the apoptosis of hepatocellular carcinoma via regulating the expression of proliferating cell nuclear antigen and cyclin D1 [34]. When ovarian cells were treated with ginsenoside Rg3, cell apoptosis was found to be induced while cell metastasis and invasion were also inhibited. Ginsenoside Rg3 inhibits cell proliferation and promotes apoptosis of ovarian cancer cells [35]. Ginsenoside Rg3 not only inhibits ovarian tumor cell proliferation and promotes its apoptosis, but also prevents tumor angiogenesis. Autophagy activity has also been found in ovarian cancer cells after ginsenoside Rg3 intervention [36].
One important cellular response to DNA damage is the induction of apoptosis to prevent daughter cells from inheriting mutations if the repair fails. Some findings demonstrated that ginsenoside Rg3 treatments induced DNA damage of non-small cell lung cancer cells (NSCLC) by affecting by activating vaccinia-related kinase 1 (VRK1)/phospho-53BP1 (P53BP1) pathway, which opens a new window for developing a new drug in the prevention of cancer progression [37]. Further work also showed that the ginsenoside Rg3 exhibits a significant anti-cancer effect on non-small cell lung cancer by inducing apoptosis via ROS/c-Jun NH2-terminal kinase (JNK)/p53 pathway [38] The tumor suppressor p53, a potent inducer of apoptosis, triggers autophagy by controlling several proteins, and plays a pivotal role in DNA damage‐induced apoptosis [39]. Rg3 inhibited the Warburg effect in ovarian cancer cells via H19/miR-324-5p/pyruvate kinase M2 (PKM2) pathway, which is associated with various biological processes including metabolism, proliferation, apoptosis, migration and invasion of tumor cells [40].
Recent work showed that ginsenoside Rg3 inhibited the proliferation and migration of human osteosarcoma cells and stimulated apoptosis in a concentration-dependent way. Ginsenoside Rg3 reduced the expression levels of Bcl2 and PI3K/AKT/mechanistic target of rapamycin (mTOR) but increased the levels of caspase3. Therefore, Ginsenoside Rg3 inhibits the proliferation of osteosarcoma cell line and induces their apoptosis by affecting apoptosis-related genes and PI3K/AKT/mTOR signaling pathway [41]. Erlotinib/Ginsenoside Rg3 treatment reduced the levels of p-epidermal growth factor receptor (EGFR), p-PI3K, and p-Akt. Ginsenoside Rg3 enhanced the efficacy of erlotinib to inhibit the proliferation of pancreatic cancer cells via induction of apoptosis and downregulation of the EGFR/ PI3Ks/AKT signaling [42].
Ginsenoside Rg3 inhibited prostate cancer cell growth via ROS-mediated cell cycle arrest [27]. Ginsenoside Rg3 improved erlotinib-induced apoptosis and increased the levels of caspase-3,9 and poly (ADP-ribose) polymerase (PARP). These results suggest that ginsenoside Rg3 may inhibit carcinoma growth via the regulation of ROS-mediated PI3K/AKT/mTOR pathway, which is involved with intrinsic apoptotic activity (Fig. 3) [43]. The apoptosis induced by ginsenoside Rg3 may be due to its steroid structure since steroid drugs have been widely reported to induce cancer cell apoptosis activity [44].
Immune regulation of ginsenoside Rg3
Both immunosuppressive and immunostimulatory are potential approaches in the cancer immunotherapy [45]. Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling mediates almost all immune regulatory processes, including those that are involved in tumor cell recognition and tumor-driven immune escape [46]. Ginsenoside Rg3 is stereospecific when stimulating the immune response, and more potent for treating cancers or other immune-mediated diseases [47]. Ginsenoside enhances the antitumor activity of Taxol on Lewis lung cancer by targeting various signaling pathways, including the interleukin-6/Jak2/STAT3 via partly just like some receptors (Fig. 4) [48, 49]. The epithelial-mesenchymal transition (EMT) is an important factor in lung cancer metastasis, and targeting EMT is a possible therapeutic strategy. Fucosyltransferase IV (FUT4) and its synthetic cancer sugar antigen Lewis Y (LeY) is often elevated in many cancers. Ginsenoside Rg3 inhibits EMT and invasion of lung cancer by down-regulating FUT4-mediated EGFR inactivation and blocking MAPK and NF-κB signal pathways [50].
Programmed death ligand 1 (PD-L1) as one the most important immune checkpoint has been verified to be involved with chemotherapy resistance in NSCLC. Rg3 reduced NSCLC cell growth and alleviated its resistance to cisplatin. PD-L1 was overexpressed in a higher level in A549/DDP cells than A549 cells. Rg3 decreased the PD-L1 expression induced by chemoresistance and resumed the T cells cytotoxicity to cancer cells. NF-κB p65 and Akt are associated with PD-L1 expression and controlled by ginsenoside Rg3. Therefore, Rg3 is regarded as a new agent targeting PD-L1 in chemotherapy refractory NSCLC [51]. Ginsenoside Rg3, is commonly used to improve the immunocompetence of cancer patients undergoing chemotherapy. Ginsenoside Rg3 has protective effects on cyclophosphamide-induced immunosuppression, which is partially related to macrophages, T cells and Th1/Th2 balance. Rg3 can improve the reduced immunocompetence after cyclophosphamide injury [47]. The anticancer effect of Rg3 may be due to its downregulation of myeloid-derived suppressor cells (MDSC) and consequent repression of cancer stemness and EMT in breast cancer. Hence, we suggest the regulation of MDSCs through Rg3 treatment as an effective therapeutic strategy for breast cancer patients [6]. Ginsenoside Rg3 can effectively induce immunogenic cell death and may be useful in dendritic cell-based anti-tumor immunotherapy [52]. The immune responses regulated by ginsenoside Rg3 may be due to its steroid structure since steroid drugs have been widely reported to induce immune responses [53].
Ginsenoside Rg3 inhibits tumor angiogenesis
The critical role of angiogenesis has been widely reported in promoting tumor growth [54, 55] and metastasis [56, 57]. As tumor neovascularization is out of control, the tumor grows rapidly. Therefore, preventing tumor neovascularization can effectively inhibit tumor growth and metastasis.
VEGF [58, 59], fibroblast growth factor (FGF), angiogenin, platelet-derived growth factor (PGF), matrix metalloproteinase (MMP) etc., all these cytokines can contribute to promoting the formation of tumor blood vessels. This inhibition of angiogenesis caused by ginsenoside was associated with decreased protein and expression of VEGF, FGF and MMP [60]. Ginsenoside Rg3 has been reported to reduce VEGF expression in the patients with acute leukemia by inactivating PI3K/Akt and extracellular-signal-regulated kinase (ERK)1/2 pathways [61]. Some work showed that ginsenoside Rg3 treatment inhibited the expression of FGF in transplanted human lung squamous carcinoma in an animal model [62]. In stimulated macrophages, Rg3 was found to suppress matrix MMP-9 activity and suppress cyclooxygenase-2 (COX-2) expression [63]. Therefore, the angiogenesis biomarkers VEGF, FGF and MMP may be the main targets of ginsenoside Rg3 in the inhibition of tumor angiogenesis (Fig. 5).
Meta-analysis shows that ginsenoside Rg3 combined with chemotherapy may enhance short-term efficacy and overall survival, alleviate treatment-induced side effects, reduce VEGF expression, increase CD4/CD8 T cell ratio, and serve as a potential therapeutic strategy for NSCLC [64]. Rg3 exerts an inhibitory effect on the transforming growth factor (TGF)/Smad and extracellular signal regulated kinase signaling pathways in human keloid fibroblasts (KF). KF proliferation, migration, invasion and angiogenesis of KF can be greatly inhibited after ginsenoside Rg3 therapy. Furthermore, the results of a vivo assay showed that ginsenoside Rg3 prevented angiogenesis and attenuated collagen accumulation in keloids [65]. Rg3 also exhibited a suppressive effect on the MMP-9 gelatinolytic activity enhanced in the HaCat keratinocytes stimulated with TNF-alpha [66]. Ginsenoside Rg3 showing inhibitory functions on tumor angiogenesis may be due to its steroid structure since steroid drugs have been widely reported to prevent tumor angiogenesis [67].
Rg3 reduces tumor metastasis
Tumor cell invasion and metastasis are closely associated with poor prognosis of cancer, which leads to cancer progression [68]. Ginsenoside Rg3 has been found to hinders cell growth, migration and invasion in human colorectal cancer (CRC) cells by downregulation of lncRNA colon cancer-associated transcript-1 (CCAT1) [69]. Rac-1/Cdc42 activity has been found to promote tumor cell invasion and metastasis [70]. Rg3 prevented thyroid cancer cell metastasis by destroying the association of actin cytoskeleton in lamellipodia by reducing the levels of Rac-1/Cdc42 in the cells. Rg3 showed good antitumor and anti-metastatic activities in vitro and in vivo, and has shown positive activities in antitumor [71]. Rho GTPase activating protein 9 (ARHGAP9), a member of RhoGAP family, has been identified to suppress the migration and invasion of hepatocellular carcinoma cells through up-regulating FOXJ2/E-cadherin [72]. Ginsenoside Rg3 hinders the metastasis and invasion of liver cancer cells by enhancing the protein levels of Rho GTPase activating protein 9 (ARHGAP9) [73]. Aquaporin 1 (AQP1) water channel participates in cancer cell proliferation, invasion, metastasis and angiogenesis, which may lead to tumor development [74]. Ginsenoside Rg3 has been reported to reduce the incidence of metastasis by inhibiting the expression of AQP1 in PC-3 M prostate cancer cells [75].
MMP-2 and MMP-9 expressions, and EMT is correlated with HCC metastasis and invasion [76]. Rg3 could inhibit migration and invasion of nasopharyngeal carcinoma (NPC) cells. This effect of Rg3 might be mediated through regulating MMP-2 and MMP-9 expressions and suppressing EMT [77]. EMT is a pivotal cellular process during which epithelial polarized cells become motile mesenchymal-appearing cells, which, in turn, cells transit between epithelial and mesenchymal states, and they play integral roles in normal tissue development and cancer metastasis [78]. TGF-β1 induces the EMT to promote tumor migration, invasion, and anoikis resistance [79]. Therefore, the inhibition of TGF-β1-induced EMT will be a potential approach to prevent tumor invasion and metastasis. Rg3 significantly decreases TGF-β1-regulated MMP-2 and activation of Smad2 and p38 MAPK (Fig. 6) [80]. Ginsenoside Rg3 showing inhibitory functions on tumor metastasis may be due to its steroid structure since steroid drugs have been widely reported to prevent tumor metastasis [81, 82].
Ginsenoside Rg3 reduces tumor chemoresistance and radioresistance
In various cancers, chemoresistance is a major hindrance for a cure [83, 84]. Therefore, it is necessary to explore a novel drug to reduce their chemoresistance. Recently, more and more researches have demonstrated that Ginsenoside Rg3 is involved in chemotherapy resistance in various types of cancers, making it a promising Chinese herbal monomer for oncotherapy [85]. EGFR/PI3K/AKT signaling pathway is associated with the degrees of tumor chemoresistance [86]. Ginsenoside Rg3 improves the anti-proliferative action of erlotinib and reduces the chemoresistance of pancreatic cancer cells by inactivating the EGFR/PI3K/Akt signaling pathway [42]. Cetuximab and chemotherapy are often used for the initial treatment for CRC. However, the cure rate for CRC is still very low because of its chemoresistance. Ginsenoside Rg3 was found to reduce the chemoresistance of CRC by inhibiting the NF-κB signal [87].
Radiation therapy is an important way for various cancer therapy. However, most patients die of the tumor recurrence when the tumors produce resistant ability to radiotherapy. Recent work showed that ginsenoside Rg3 enhances the therapeutic results of radiotherapy for CRC by inhabiting NF-κB and NF-κB-mediated genes, resulting in the prevention of CRC development and prolongation of the lifespan of an animal model [88]. These results suggest that ginsenoside Rg3 is a potential drug to reduce tumor chemoresistance and radioresistance. Ginsenoside Rg3 increasing the tumor sensitivity to chemical therapy may be also due to its steroid structure since steroid drugs have been widely reported to reduce tumor chemoresistance [89].
The stereoselective effects of two epimers of Rg3
Rg3 has two stereoisomeric pairs, 20(S)‐ginsenoside Rg3 [20(S)‐Rg3] and 20(R)‐ginsenoside Rg3 [20(R)‐Rg3] with different pharmacological functions due to their different structures. Compared with 20(S)‐Rg3, 20(R)‐Rg3 shows higher anticancer activities for hepatocellular carcinoma study BY stimulating ConA‐induced lymphocyte proliferation and increasing the levels of Th1‐type cytokines interleukin‐2 and interferon‐γ [90]. Further work showed that 20(R)‐Rg3 may have more potency and efficacy than 20(S)‐Rg3 by preventing the migration and invasion of breast cancer cell line MDA-MB-231 [91]. However, different stereoisomer-specific anticancer activities have also been reported that 20(S)‐Rg3 but not 20 (R)-Rg3 promotes cancer cell death in a dose-dependent manner by inducing the apoptosis of human liver cancer cell line HepG2 via the regulation of the levels of Bcl2 and Fas [92]. Much work is required to understand the differences caused by stereoisomer-specific anticancer activities of Rg3.
Rg3 metabolism and pharmacokinetics
The half-life of Rg3, absorption and tissue distribution will be critical properties for first-pass success of a candidate antitumor drug. Metabolism and pharmacokinetic studies are necessary to understand these important properties. A big concern about clinical indication of ginsenoides Rg3 in particular is its high metabolic rate of these molecules. Pharmacokinetics study shows that an average half-life of Rg3 is less than 20 min when the ginsenoside was intravenously dosed at 5 mg/kg in rat, and no Rg3 was detected in rat plasma if oral administration at 100 mg/kg [93]. Other metabolism data approve that Rg3 can be easily transformed to active ingredients by gut microbiota [94]. 20(S)-Rg3 was thought to be more predominant in the liver than kidney [95]. To avoid short half-life, Rg3 nanoparticles were injected into the mice tail vein. The concentrations of Rg3 nanoformulations in the liver, spleen and lung tissue were higher than the control group only with Rg3 monomer at the end of experiments [96]. Comparatively, human being is quite different from rats in the metabolism and pharmacokinetics of Rg3, can be detected in the plasma for 8 and up to 216 h after oral or intramuscular administration [97].
Clinical indication of Rg3
The trials of Rg3 in combination with chemotherapy have been reported to exert better therapeutic effects than chemotherapy alone and increase the life expectancy of NSCLC patients after cancer surgery. The mechanism may be associated the improvement of immune and anti-tumor activities [98]. Acquired resistance is the main factor for limiting the usage of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in the prevention of lung cancer development. Rg3 helps to increase progression-free survival (PFS) and improve objective response rate (ORR) after EGFR-TKI treatment in NSCLC patients [99]. Transcatheter arterial chemoembolization (TACE) is a marginally invasive method in the therapy of various tumors. However, TACE shows the risks and side effects of both chemotherapy and embolization. The combination of TACE and Rg3 can increase overall survival rate when compared to those who only received TACE in HCC patients. Rg3 intervention inclines to attenuate adverse effects associated with TACE [100].
The differences between the present review and previous reviews
There are some review papers on the topic describing the anti-cancer properties of Rg3 and the differences are significant between the present review and previous reviews. Sun et al. summarized the main anticancer mechanisms, also including apoptosis, inhibition of cancer cell proliferation, metastasis and angiogenesis, and improvement of immunity [101]. Nakhjavani et al. reviewed the main anticancer mechanisms of Rg3 but only for breast cancer [97]. However, the main anti-inflammatory properties related signaling pathways of Rg3 were neither included nor discussed in these analyses. Although antioxidant properties were mentioned in these reviews, the possible mechanisms were not explored either. In the present review, we find that Ginsenoside Rg3 improves anti-inflammatory capacity by affecting PI3K/AKT/mTOR pathway signaling pathway through TLR4. Ginsenoside Rg3 increases antioxidant properties by affecting the activities antioxidant enzymes (SOD, CAT, GPx, GR), which are involved in scavenging ROS molecules O2., O2−, ·OH and H2O2. Deciphering related signaling pathway will be beneficial to understand the complex molecular mechanisms of Rg3 action, and becomes the main topics in the present review. Comparatively, the previous reviews mainly focus on the potential molecular targets of Rg3.
Conclusion
Ginsenoside Rg3 has shown remarkable anti-tumor functions with few side effects both in vivo and vitro experiments, including lung, colon, breast and colorectal cancers. Furthermore, ginsenoside Rg3 improves the therapeutic results and efficacy of chemotherapy and radiotherapy. Ginsenoside Rg3 is a safe and effective anti-tumor Chinese medicine ingredient by affecting multiple antioxidant, anti-inflammatory, and immune signaling pathways, inhibiting tumor cell proliferation and neovascularization, promoting tumor cell apoptosis, and reversing tumor chemoresistance, etc.,. Ginsenoside Rg3 shows various inhibitory functions on many types of cancer may be also due to its steroid structure. There are still some limitations of ginsenoside Rg3 utilization: its functional molecular mechanisms remain widely unclear. A few clinical trials have been reported to treat cancers using Rg3, including NSCLC and HCC [97]. Furthermore, stereoselective inhibitory functions of Ginsenoside Rg3, Rg2, Rh2, Rh1 and Proropanaxadiol Epimers on Six UDP-gluronosyltransferases have been evaluated in human liver microsomes [102]. However, there is still lack of the related information on the clinical trials. Therefore, much work focusing on many clinical experiments is highly needed and the optimization of Rg3 usage will be worth for further investigating.
References
Lee DY, Park CW, Lee SJ et al (2019) Anti-cancer effects of panax ginseng berry polysaccharides via activation of immune-related cells. Front Pharmacol 10:1411
Lee JH, Leem DG, Chung KS et al (2018) Panaxydol derived from panax ginseng inhibits G1 cell cycle progression in non-small cell lung cancer via upregulation of intracellular Ca(2+) levels. Biol Pharm Bull 41(11):1701–1707
Martoni AA, Cavanna L, Porzio G (2018) Letter to the editor: panax ginseng for cancer-related fatigue. J Natl Compr Canc Netw 16(4):342
Wang Z, Liu R, Chen L et al (2020) Pharmacokinetics of ginsenoside Rh2, the major anticancer ingredient of ginsenoside H dripping pills, in healthy subjects. Clin Pharmacol Drug Dev. https://doi.org/10.1002/cpdd.877
Chu Y, Zhang W, Kanimozhi G et al (2020) Ginsenoside Rg1 induces apoptotic cell death in triple-negative breast cancer cell lines and prevents carcinogen-induced breast tumorigenesis in sprague dawley rats. Evid Based Complem Alternat Med 2020:8886955
Song JH, Eum DY, Park SY et al (2020) Inhibitory effect of ginsenoside Rg3 on cancer stemness and mesenchymal transition in breast cancer via regulation of myeloid-derived suppressor cells. PLoS ONE 15(10):e0240533
Park YJ, Cho M, Choi G et al (2020) A critical regulation of Th17 cell responses and autoimmune neuro-inflammation by ginsenoside Rg3. Biomolecules 10(1):1–7
Zhou T, Sun L, Yang S et al (2020) 20 (S)-ginsenoside rg3 protects kidney from diabetic kidney disease via renal inflammation depression in diabetic rats. J Diabetes Res. https://doi.org/10.1155/2020/7152176
Wang H, Wu W, Wang G et al (2019) Protective effect of ginsenoside Rg3 on lung injury in diabetic rats. J Cell Biochem 120(3):3323–3330
Jeong D, Irfan M, Kim SD et al (2017) Ginsenoside Rg3-enriched red ginseng extract inhibits platelet activation and in vivo thrombus formation. J Ginseng Res 41(4):548–555
Akbari A, Khayamzadeh M, Salmanian R et al (2019) National cancer mortality-to-incidence ratio (MIR) in Iran (2005–2014). Int J Cancer Manage 12(6):1–6
Shi J, Xue J (2019) Inflammation and development of pancreatic ductal adenocarcinoma. Chin Clin Oncol 8(2):19–19
Bessler H, Djaldetti M (2017) Capsaicin modulates the immune cross talk between human mononuclears and cells from two colon carcinoma lines. Nutr Cancer 69(1):14–20
Lee HL, Jang JW, Lee SW et al (2019) Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep 9(1):1–8
Sheikhpour E, Noorbakhsh P, Foroughi E et al (2018) A survey on the role of interleukin-10 in breast cancer: a narrative. Rep Biochem Mol Biol 7(1):30
Park Y-J, Cho M, Choi G et al (2020) A critical regulation of Th17 cell responses and autoimmune neuro-inflammation by ginsenoside Rg3. Biomolecules 10(1):122
Tu C, Wan B, Zeng Y (2020) Ginsenoside Rg3 alleviates inflammation in a rat model of myocardial infarction via the SIRT1/NF-κB pathway. Exp Therap Med 20(6):1–1
Yang J, Li S, Wang L et al (2018) Ginsenoside Rg3 attenuates lipopolysaccharide-induced acute lung injury via MerTK-dependent activation of the PI3K/AKT/mTOR pathway. Front Pharmacol 9:850
Xin C, Kim J, Quan H et al (2019) Ginsenoside Rg3 promotes Fc gamma receptor-mediated phagocytosis of bacteria by macrophages via an extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent mechanism. Int Immunopharmacol 77:105945
Hodge G, Roscioli E, Jersmann H et al (2016) Steroid resistance in COPD is associated with impaired molecular chaperone Hsp90 expression by pro-inflammatory lymphocytes. Respir Res 17(1):135
Sheng L, Lu B, Chen H et al (2019) Marine-steroid derivative 5α-androst-3β, 5α, 6β-triol protects retinal ganglion cells from ischemia-reperfusion injury by activating Nrf2 pathway. Marine Drugs 17(5):267
Misra P (2020) Dexamethasone may reduce mortality rate in COVID-19. Homœopathic Links.
Hayes JD, Dinkova-Kostova AT, Tew KD (2020) Oxidative stress in cancer. Cancer Cell 10:167–197
Choudhary MI (2020) Emerging classes of antioxidant to cancer therapy: a review of clinical and experimental studies. ar**Xiv:20***03.04538.
Sun HY, Lee JH, Han Y-S et al (2016) Pivotal roles of ginsenoside Rg3 in tumor apoptosis through regulation of reactive oxygen species. Anticancer Res 36(9):4647–4654
Morrell CN (2008) Reactive oxygen species: finding the right balance. Am Heart Assoc 10:571–572
Peng Y, Zhang R, Yang X et al (2019) Ginsenoside Rg3 suppresses the proliferation of prostate cancer cell line PC3 through ROS-induced cell cycle arrest. Oncol Lett 17(1):1139–1145
Wei X, Su F, Su X et al (2012) Stereospecific antioxidant effects of ginsenoside Rg3 on oxidative stress induced by cyclophosphamide in mice. Fitoterapia 83(4):636–642
Lee H, Kim J, Lee SY et al (2012) Processed Panax ginseng, sun ginseng, decreases oxidative damage induced by tert-butyl hydroperoxide via regulation of antioxidant enzyme and anti-apoptotic molecules in HepG2 cells. J Ginseng Res 36(3):248
Mwaheb M, Mohammed A, Al-Galad G et al (2017) Effect of nandrolone decanoate (anabolic steroid) on the liver and kidney of male albino rats and the role of antioxidant (antox-silymarin) as adjuvant therapy. J Drug Metab Toxicol 8(1):1–11
Carneiro BA, El-Deiry WS (2020) Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 56:1–23
Hong S, Cai W, Huang Z et al (2020) Ginsenoside Rg3 enhances the anticancer effect of 5-FU in colon cancer cells via the PI3K/AKT pathway. Oncol Rep 44(4):1333–1342
Qiu R, Qian F, Wang X et al (2019) Targeted delivery of 20 (S)-ginsenoside Rg3-based polypeptide nanoparticles to treat colon cancer. Biomed Microdev 21(1):18
Shan K, Wang Y, Hua H et al (2019) Ginsenoside Rg3 combined with oxaliplatin inhibits the proliferation and promotes apoptosis of hepatocellular carcinoma cells via downregulating PCNA and cyclin D1. Biol Pharm Bull 42(6):900–905
Zhao L, Shou H, Chen L et al (2019) Effects of ginsenoside Rg3 on epigenetic modification in ovarian cancer cells. Oncol Rep 41(6):3209–3218
Zheng X, Chen W, Hou H et al (2017) Ginsenoside 20 (S)-Rg3 induced autophagy to inhibit migration and invasion of ovarian cancer. Biomed Pharmacother 85:620–626
Liu T, Zuo L, Guo D et al (2019) Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1/P53BP1 pathway. Biomed Pharmacother 120:109483
Wu Q, Deng J, Fan D et al (2018) Ginsenoside Rh4 induces apoptosis and autophagic cell death through activation of the ROS/JNK/p53 pathway in colorectal cancer cells. Biochem Pharmacol 148:64–74
Yogosawa S, Yoshida K (2018) Tumor suppressive role for kinases phosphorylating p53 in DNA damage-induced apoptosis. Cancer Sci 109(11):3376–3382
Zheng X, Zhou Y, Chen W et al (2018) Ginsenoside 20 (S)-Rg3 prevents PKM2-targeting miR-324-5p from H19 sponging to antagonize the Warburg effect in ovarian cancer cells. Cell Physiol Biochem 51(3):1340–1353
Li Y, Lu J, Bai F et al (2018) Ginsenoside Rg3 suppresses proliferation and induces apoptosis in human osteosarcoma. BioMed Res Int. https://doi.org/10.1155/2018/4306579
Jiang J, Yuan Z, Sun Y et al (2017) Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway. Biomed Pharmacother 96:619–625
Jiang J-W, Chen X-M, Chen X-H et al (2011) Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway. World J Gastroenterol 17(31):3605
Lv L, Zheng L, Dong D et al (2013) Dioscin, a natural steroid saponin, induces apoptosis and DNA damage through reactive oxygen species: a potential new drug for treatment of glioblastoma multiforme. Food Chem Toxicol 59:657–669
Whiteside TL (2017) The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. Fut Oncol 13(28):2583–2592
Owen KL, Brockwell NK, Parker BS (2019) JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers 11(12):2002
Liu X, Zhang Z, Liu J et al (2019) Ginsenoside Rg3 improves cyclophosphamide-induced immunocompetence in Balb/c mice. Int Immunopharmacol 72:98–111
Kim SK, Chung J-H, Lee B-C et al (2014) Influence of Panax ginseng on alpha-adrenergic receptor of benign prostatic hyperplasia. Int Neurourol J 18(4):179
Tang M, Huang L-L, Du Q-Q et al (2020) Ginsenoside 3β-O-Glc-DM (C3DM) enhances the antitumor activity of Taxol on Lewis lung cancer by targeting the interleukin-6/Jak2/STAT3 and interleukin-6/AKT signaling pathways. World J Tradition Chin Med 6:434–440
Tian L, Shen D, Li X et al (2016) Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4. Oncotarget 7(2):1619
Jiang Z, Yang Y, Yang Y et al (2017) Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. Biomed Pharmacother 96:378–383
Son KJ, Choi KR, Lee SJ et al (2016) Immunogenic cell death induced by ginsenoside Rg3: significance in dendritic cell-based anti-tumor immunotherapy. Immune Netw 16(1):75–84
Gambhir L, Checker R, Sharma D et al (2015) Thiol dependent NF-κB suppression and inhibition of T-cell mediated adaptive immune responses by a naturally occurring steroidal lactone Withaferin A. Toxicol Appl Pharmacol 289(2):297–312
Kiang KM, Zhang P, Li N et al (2020) Loss of cytoskeleton protein ADD3 promotes tumor growth and angiogenesis in glioblastoma multiforme. Cancer Lett 474:118–126
Nuevo-Tapioles C, Santacatterina F, Stamatakis K et al (2020) Coordinate beta-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth. Nat Commun 11(1):3606
Zeng T, Tang Z, Liang L et al (2020) PDSS2-Del2, a new variant of PDSS2, promotes tumor cell metastasis and angiogenesis in hepatocellular carcinoma via activating NF-kappaB. Mol Oncol 14:3184–3197
Fu LQ, Du WL, Cai MH et al (2020) The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol 353:104119
Jiang S, Gao Y, Yu QH et al (2020) P-21-activated kinase 1 contributes to tumor angiogenesis upon photodynamic therapy via the HIF-1alpha/VEGF pathway. Biochem Biophys Res Commun 526(1):98–104
Zhou H, Binmadi NO, Yang YH et al (2020) Retraction Note to: semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression. Angiogenesis 23(2):267
Nakhjavani M, Smith E, Townsend AR et al (2020) Anti-angiogenic properties of ginsenoside Rg3. Molecules 25(21):1–9
Zeng D, Wang J, Kong P et al (2014) Ginsenoside Rg3 inhibits HIF-1α and VEGF expression in patient with acute leukemia via inhibiting the activation of PI3K/Akt and ERK1/2 pathways. Int J Clin Exp Pathol 7(5):2172
Wang X, Li K, Lin N et al (2010) Effects of ginsenoside Rg3 on growth and VEGF, bFGF expressions of transplanted human lung squamous cell carcinoma in nude mice. Liaoning J Tradition Chin Med 2:64
Shin Y-M, Jung H-J, Choi W-Y et al (2013) Antioxidative, anti-inflammatory, and matrix metalloproteinase inhibitory activities of 20 (S)-ginsenoside Rg3 in cultured mammalian cell lines. Mol Biol Rep 40(1):269–279
Xu T, Jin Z, Yuan Y et al (2016) Ginsenoside Rg3 serves as an adjuvant chemotherapeutic agent and VEGF inhibitor in the treatment of non-small cell lung cancer: a meta-analysis and systematic review. Evid Based Complement Alternat Med 2016:7826753
Tang M, Bian W, Cheng L et al (2018) Ginsenoside Rg3 inhibits keloid fibroblast proliferation, angiogenesis and collagen synthesis in vitro via the TGFbeta/Smad and ERK signaling pathways. Int J Mol Med 41(3):1487–1499
Shin YM, Jung HJ, Choi WY et al (2013) Antioxidative, anti-inflammatory, and matrix metalloproteinase inhibitory activities of 20(S)-ginsenoside Rg3 in cultured mammalian cell lines. Mol Biol Rep 40(1):269–279
Martens B, Drebert Z (2019) Glucocorticoid-mediated effects on angiogenesis in solid tumors. J Steroid Biochem Mol Biol 188:147–155
Zhang S, Sun WY, Wu JJ et al (2016) Decreased expression of the type III TGF-beta receptor enhances metastasis and invasion in hepatocellullar carcinoma progression. Oncol Rep 35(4):2373–2381
Li J, Qi Y (2019) Ginsenoside Rg3 inhibits cell growth, migration and invasion in Caco-2 cells by downregulation of lncRNA CCAT1. Exp Mol Pathol 106:131–138
Guo J, Yu X, Gu J et al (2016) Regulation of CXCR4/AKT-signaling-induced cell invasion and tumor metastasis by RhoA, Rac-1, and Cdc42 in human esophageal cancer. Tumour Biol 37(5):6371–6378
Wu W, Zhou Q, Zhao W (2018) Ginsenoside Rg3 inhibition of thyroid cancer metastasis is associated with alternation of actin skeleton. J Med Food 21(9):849–857
Zhang H, Tang QF, Sun MY et al (2018) ARHGAP9 suppresses the migration and invasion of hepatocellular carcinoma cells through up-regulating FOXJ2/E-cadherin. Cell Death Dis 9(9):916
Sun MY, Song YN, Zhang M et al (2019) Ginsenoside Rg3 inhibits the migration and invasion of liver cancer cells by increasing the protein expression of ARHGAP9. Oncol Lett 17(1):965–973
Imaizumi H, Ishibashi K, Takenoshita S et al (2018) Aquaporin 1 expression is associated with response to adjuvant chemotherapy in stage II and III colorectal cancer. Oncol Lett 15(5):6450–6456
Pan XY, Guo H, Han J et al (2012) Ginsenoside Rg3 attenuates cell migration via inhibition of aquaporin 1 expression in PC-3M prostate cancer cells. Eur J Pharmacol 683(1–3):27–34
Ren T, Zhu L, Cheng M (2017) CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma. Am J Transl Res 9(6):2824
Wang D, Wu C, Liu D et al (2019) Ginsenoside Rg3 inhibits migration and invasion of nasopharyngeal carcinoma cells and suppresses epithelial mesenchymal transition. Biomed Res Int 2019:8407683
Heerboth S, Housman G, Leary M et al (2015) EMT and tumor metastasis. Clin Transl Med 4(1):6
Ko H (2015) Geraniin inhibits TGF-β1-induced epithelial–mesenchymal transition and suppresses A549 lung cancer migration, invasion and anoikis resistance. Bioorg Med Chem Lett 25(17):3529–3534
Kim Y-J, Choi W-I, Jeon B-N et al (2014) Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-β1-induced epithelial–mesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance. Toxicology 322:23–33
Hu Y, Wu A-Y, Xu C et al (2019) MicroRNA-449a inhibits tumor metastasis through AKT/ERK1/2 inactivation by targeting steroid receptor coactivator (SRC) in endometrial cancer. J Cancer 10(2):547
Ryken TC, Kuo JS, Prabhu RS et al (2019) Congress of neurological surgeons systematic review and evidence-based guidelines on the role of steroids in the treatment of adults with metastatic brain tumors. Neurosurgery 84:E189
Amrutkar M, Gladhaug IP (2017) Pancreatic cancer chemoresistance to gemcitabine. Cancers 9(11):157
Leung CS, Yeung T-L, Yip K-P et al (2018) Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Investig 128(2):589–606
Pan L, Zhang T, Cao H et al (2020) Ginsenoside Rg3 for chemotherapy-induced myelosuppression: a meta-analysis and systematic review. Front Pharmacol 11:649
Zhang Y, Han CY, Duan FG et al (2019) p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling. Cancer Cell Int 19(1):188
Kim SM, Lee SY, Yuk DY et al (2009) Inhibition of NF-κB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch Pharmacal Res 32(5):755–765
Liu T, Duo L, Duan P (2018) Ginsenoside Rg3 sensitizes colorectal cancer to radiotherapy through downregulation of proliferative and angiogenic biomarkers. Evid-Based Complem Altern Med. https://doi.org/10.1155/2018/1580427
Mijatovic T, Dufrasne F, Kiss R (2012) Cardiotonic steroids-mediated targeting of the Na+/K+-ATPase to combat chemoresistant cancers. Curr Med Chem 19(5):627–646
Wu R, Ru Q, Chen L et al (2014) Stereospecificity of ginsenoside Rg3 in the promotion of cellular immunity in hepatoma H22-bearing mice. J Food Sci 79(7):H1430–H1435
Nakhjavani M, Palethorpe HM, Tomita Y et al (2019) Stereoselective anti-cancer activities of ginsenoside Rg3 on triple negative breast cancer cell models. Pharmaceuticals 12(3):117
Cheong JH, Kim H, Hong MJ et al (2015) Stereoisomer-specific anticancer activities of ginsenoside Rg3 and Rh2 in HepG2 cells: disparity in cytotoxicity and autophagy-inducing effects due to 20 (S)-epimers. Biol Pharm Bull 38(1):102–108
Qian T, Cai Z, Wong RN et al (2005) In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J Chromatogr B 816(1–2):223–232
Cai Z, Qian T, Wong RN et al (2003) Liquid chromatography–electrospray ionization mass spectrometry for metabolism and pharmacokinetic studies of ginsenoside Rg3. Anal Chim Acta 492(1–2):283–293
Sung Kang K, Young Kim H, Yamabe N et al (2007) Preventive effect of 20 (S)-ginsenoside Rg3 against lipopolysaccharide-induced hepatic and renal injury in rats. Free Radic Res 41(10):1181–1188
Pan C, Wang Y et al (2016) Study on mice in-vivo targeting of three ginsenoside Rg3 nanoformulations. Tradit Chin Drug Res Clin Pharmacol 6:17
Nakhjavani M, Hardingham JE, Palethorpe HM et al (2019) Ginsenoside Rg3: potential molecular targets and therapeutic indication in metastatic breast cancer. Medicines 6(1):17
Lu P, Su W, Miao ZH et al (2008) Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer. Chin J Integr Med 14(1):33–36
Li Y, Wang Y, Niu K et al (2016) Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation. Oncotarget 7(43):70535–70545
Zhou B, Yan Z, Liu R et al (2016) Prospective study of transcatheter arterial chemoembolization (TACE) with ginsenoside Rg3 versus TACE alone for the treatment of patients with advanced hepatocellular carcinoma. Radiology 280(2):630–639
Sun M, Ye Y, Xiao L et al (2017) Anticancer effects of ginsenoside Rg3. Int J Mol Med 39(3):507–518
Bae PJ, Doyun K, Fen ZY et al (2014) Stereoselective inhibitory assessment of ginsenoside Rg3, Rg2, Rh2, Rh1 and proropanaxadiol epimers on six UDP-gluronosyltransferases in human liver microsomes. 추계총회 및 학술대회 pp 304–304
Zhang Y-H, Li H-D, Li B et al (2014) Ginsenoside Rg3 induces DNA damage in human osteosarcoma cells and reduces MNNG-induced DNA damage and apoptosis in normal human cells. Oncol Rep 31(2):919–925
Kim B-M, Kim D-H, Park J-H et al (2013) Ginsenoside Rg3 induces apoptosis of human breast cancer (MDA-MB-231) cells. J Cancer Prev 18(2):177
He K, Liu Y, Yang Y et al (2005) A dammarane glycoside derived from ginsenoside Rb3. Chem Pharm Bull (Tokyo) 53(2):177–179
Kim B-M, Kim D-H, Park J-H et al (2014) Ginsenoside Rg3 inhibits constitutive activation of NF-κB signaling in human breast cancer (MDA-MB-231) cells: ERK and Akt as potential upstream targets. J Cancer Prev 19(1):23
Chen X-p, Qian L-l, Jiang H et al (2011) Ginsenoside rg3 inhibits cxcr 4 expression and related migrations in a breast cancer cell line. Int J Clin Oncol 16(5):519–523
Yuan H-D, Quan H-Y, Zhang Y et al (2010) 20 (S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway. Mol Med Rep 3(5):825–831
Lee SY, Kim GT, Roh SH et al (2009) Proteomic analysis of the anti-cancer effect of 20S-ginsenoside Rg3 in human colon cancer cell lines. Biosci Biotechnol Biochem 56:0903051360–0903051360
Luo X, Wang C-Z, Chen J et al (2008) Characterization of gene expression regulated by American ginseng and ginsenoside Rg3 in human colorectal cancer cells. Int J Oncol 32(5):975–983
He B-C, Gao J-L, Luo X et al (2011) Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ss-catenin signaling. Int J Oncol 38(2):437–445
Junmin S, Hongxiang L, Zhen L et al (2015) Ginsenoside Rg3 inhibits colon cancer cell migration by suppressing nuclear factor kappa B activity. J Tradit Chin Med 35(4):440–444
Chang L, Huo B, Lv Y et al (2014) Ginsenoside Rg3 enhances the inhibitory effects of chemotherapy on esophageal squamous cell carcinoma in mice. Mol Clin Oncol 2(6):1043–1046
Qiu X-M, Bai X, Jiang H-F et al (2014) 20-(s)-ginsenoside Rg3 induces apoptotic cell death in human leukemic U937 and HL-60 cells through PI3K/Akt pathways. Anticancer Drugs 25(9):1072–1080
Wu K, Li N, Sun H et al (2015) Endoplasmic reticulum stress activation mediates Ginseng Rg3-induced anti-gallbladder cancer cell activity. Biochem Biophys Res Commun 466(3):369–375
Zhang F, Li M, Wu X et al (2015) 20 (S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway. Drug Design Dev Therapy 9:3969
Park E-H, Kim Y-J, Yamabe N et al (2014) Stereospecific anticancer effects of ginsenoside Rg3 epimers isolated from heat-processed American ginseng on human gastric cancer cell. J Ginseng Res 38(1):22–27
Aziz F, Wang X, Liu J et al (2016) Ginsenoside Rg3 induces FUT4-mediated apoptosis in H. pylori CagA-treated gastric cancer cells by regulating SP1 and HSF1 expressions. Toxicol In Vitro 31:158–166
Kim BJ, Nah SY, Jeon JH et al (2011) Transient receptor potential melastatin 7 channels are involved in ginsenoside Rg3-induced apoptosis in gastric cancer cells. Basic Clin Pharmacol Toxicol 109(4):233–239
Choi YJ, Lee HJ, Kang DW et al (2013) Ginsenoside Rg3 induces apoptosis in the U87MG human glioblastoma cell line through the MEK signaling pathway and reactive oxygen species. Oncol Rep 30(3):1362–1370
Sin S, Kim SY, Kim SS (2012) Chronic treatment with ginsenoside Rg3 induces Akt-dependent senescence in human glioma cells. Int J Oncol 41(5):1669–1674
Joo EJ, Chun J, Ha YW et al (2015) Novel roles of ginsenoside Rg3 in apoptosis through downregulation of epidermal growth factor receptor. Chem Biol Interact 233:25–34
Lee J-Y, Jung KH, Morgan MJ et al (2013) Sensitization of TRAIL-induced cell death by 20 (S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells. Mol Cancer Ther 12(3):274–285
Xie Q, Wen H, Zhang Q et al (2017) Inhibiting PI3K-AKt signaling pathway is involved in antitumor effects of ginsenoside Rg3 in lung cancer cell. Biomed Pharmacother 85:16–21
Zhang C, Liu L, Yu Y et al (2012) Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells. Mol Med Rep 5(5):1295–1298
Park H-M, Kim S-J, Kim J-S et al (2012) Reactive oxygen species mediated ginsenoside Rg3-and Rh2-induced apoptosis in hepatoma cells through mitochondrial signaling pathways. Food Chem Toxicol 50(8):2736–2741
Shan X, Aziz F, Tian LL et al (2015) Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression. Int J Oncol 46(4):1667–1676
Luo Y, Zhang P, Zeng HQ et al (2015) Ginsenoside Rg3 induces apoptosis in human multiple myeloma cells via the activation of Bcl-2-associated X protein. Mol Med Rep 12(3):3557–3562
Shan X, Tian LL, Zhang YM et al (2015) Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-κB/p65 signaling pathway to promote melanoma cell death. Int J Oncol 47(2):701–709
Shan X, Fu Y-S, Aziz F et al (2014) Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation. PLoS ONE 9(12):e115401
Li Y, Yang T, Li J et al (2016) Inhibition of multiple myeloma cell proliferation by ginsenoside Rg3 via reduction in the secretion of IGF-1. Mol Med Rep 14(3):2222–2230
Chen J, Peng H, Ou-Yang X et al (2008) Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells. Melanoma Res 18(5):322–329
Lee SG, Kang YJ, Nam J-O (2015) Anti-metastasis effects of ginsenoside Rg3 in B16F10 cells. J Microbiol Biotechnol 25(12):1997–2006
Wang J-H, Nao J-F, Zhang M et al (2014) 20 (s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer HO-8910 cells through PI3K/Akt and XIAP pathways. Tumor Biol 35(12):11985–11994
Guo J-Q, Zheng Q-H, Chen H et al (2014) Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE-cadherin/EphA2/MMP9/MMP2 expression. Int J Oncol 45(3):1065–1072
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Liu, Z., Liu, T., Li, W. et al. Insights into the antitumor mechanism of ginsenosides Rg3. Mol Biol Rep 48, 2639–2652 (2021). https://doi.org/10.1007/s11033-021-06187-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-021-06187-2